CEO Michael Cloonan was paid $6,981,217 in fiscal year 2025, ↑ up 87.3% from fiscal year 2024 (SEC filing 0001628280-26-027489 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,981,217 ↑ Michael Cloonan total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
SION's next annual pay disclosure, estimated April 25, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Cloonan | $646,580 | $0 | $0 | $5,950,575 | $374,062 | $0 | $10,000 | $6,981,217 |
| President and Chief Executive Officer | ||||||||
| Caroline Stark Beer | 158,945 | 30,000 | 0 | 5,324,783 | 71,599 | 0 | 7,569 | 5,592,896 |
| Chief Business Officer | ||||||||
| Elena Ridloff | 506,677 | 0 | 0 | 2,085,765 | 254,925 | 0 | 10,000 | 2,857,367 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Cloonan | $6,981,217 | $3,726,785 | — | ↑ +3,254,432 |
| Caroline Stark Beer | 5,592,896 | — | — | — |
| Elena Ridloff | 2,857,367 | 1,300,647 | — | ↑ +1,556,720 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Sionna Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SION reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Bruce Booth, D.Phil | Independent Director | $281,239 |
| H. Edward Fleming Jr., M.D | Independent Director | $283,039 |
| Joanne Louise Viney, Ph.D | Independent Director | $810,316 |
| Joshua Resnick, M.D., M.B.A | Independent Director | $275,839 |
| Laurie Stelzer, M.B.A | Independent Director | $299,639 |
| Lucian Iancovici, M.D | Independent Director | — |
| Marcella Kuhlman Ruddy, M.D | Independent Director | $803,566 |
| Paul Clancy, M.B.A | Independent Director | $323,139 |
| Peter A. Thompson, M.D | Independent Director | $279,889 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Caroline Stark Beer | Option | 255,000 | 28.47 | — |
| Michael Cloonan | Option | 81,985 | 6.11 | — |
| Michael Cloonan | Option | 4,567 | 6.11 | — |
| Michael Cloonan | Option | 369,554 | 6.11 | — |
| Michael Cloonan | Option | 124,941 | 18 | — |
| Michael Cloonan | Option | 13,853 | 6.11 | — |
| Michael Cloonan | Option | 356,450 | 18 | — |
Our executive compensation program is designed to attract, motivate and retain key employees who best represent our company values and can make significant contributions towards achieving our business purpose. The program is structured to incentivize our executive team based on the achievement of key performance goals, and to align their interests with those of our stockholders, reflecting a pay-for-performance philosophy that supports our business strategy while not encouraging excessive risk-taking.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joanne Louise Viney, Ph.DIndependent · Compensation (Chair) · Audit · Nominating/Governance · Newly elected | $50,244 | — | $760,072 | — | $0 | $810,316 |
| Marcella Kuhlman Ruddy, M.DIndependent · Nominating and Corporate Governance · Audit · Compensation · Newly elected | 43,494 | — | 760,072 | — | 0 | 803,566 |
| Paul Clancy, M.B.AIndependent · Audit · Nominating and Corporate Governance (Chair) | 83,300 | — | 239,839 | — | 0 | 323,139 |
| Laurie Stelzer, M.B.AIndependent · Audit · Compensation · Nominating/Governance | 59,800 | — | 239,839 | — | 0 | 299,639 |
| H. Edward Fleming Jr., M.DIndependent · Audit · Compensation · Nominating/Governance | 43,200 | — | 239,839 | — | 0 | 283,039 |
| Bruce Booth, D.PhilIndependent | 41,400 | — | 239,839 | — | 0 | 281,239 |
| Peter A. Thompson, M.DIndependent | 40,050 | — | 239,839 | — | 0 | 279,889 |
| Joshua Resnick, M.D., M.B.AIndependent · Compensation | 36,000 | — | 239,839 | — | 0 | 275,839 |
| Lucian Iancovici, M.DIndependent | 0 | 0 | 0 | — | 0 | 0 |
| Michael Cloonan, M.B.AEmployee director · Audit · Compensation · Nominating/Governance | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 12,000 / 9,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $397,488 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $397,488 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sionna Therapeutics | 2025 | Michael Cloonan | $646,580 | $0 | $5,950,575 | $374,062 | $6,981,217 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Michael Cloonan | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Executive Compensation”. As printed: 6,981,217. Filing ↗machine: r2 · c42 · span 310366–310375 |
| 2 | Section 01, Caroline Stark Beer | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Executive Compensation”. As printed: 5,592,896. Filing ↗machine: r6 · c42 · span 321472–321481 |
| 3 | Section 01, Elena Ridloff | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Executive Compensation”. As printed: 2,857,367. Filing ↗machine: r4 · c42 · span 315958–315967 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-02 | 0001628280-26-012996 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Joanne Louise Viney, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 810,316. Filing ↗machine: span 263136–263442 |
| 6 | Section 08, Marcella Kuhlman Ruddy, M.D | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 803,566. Filing ↗machine: span 258854–259160 |
| 7 | Section 08, Paul Clancy, M.B.A | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 323,139. Filing ↗machine: span 253143–253449 |
| 8 | Section 08, Laurie Stelzer, M.B.A | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 299,639. Filing ↗machine: span 260277–260583 |
| 9 | Section 08, H. Edward Fleming Jr., M.D | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 283,039. Filing ↗machine: span 254572–254878 |
| 10 | Section 08, Bruce Booth, D.Phil | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 281,239. Filing ↗machine: span 251723–252029 |
| 11 | Section 08, Peter A. Thompson, M.D | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 279,889. Filing ↗machine: span 261705–262011 |
| 12 | Section 08, Joshua Resnick, M.D., M.B.A | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 275,839. Filing ↗machine: span 257425–257731 |
| 13 | Section 08, Lucian Iancovici, M.D | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 08, Michael Cloonan, M.B.A | DEF 14A | 2026-04-27 | 0001628280-26-027489 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 15 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 397,488 + equity 0 + all other 0 = 397,488, summed across the director compensation table rows.machine: formula: Σ = 397,488 |
| 17 | Sionna Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027489 | CEO total compensation as printed in Sionna Therapeutics's own proxy. As printed: 6,981,217. Filing ↗machine: r2 · c42 · span 310366–310375 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.